| Treatment group | P valueb | |
---|---|---|---|
Paraffin therapy | US therapy | ||
(n = 23) | (n = 24) | ||
Functional status score | Â | Â | 0.04 |
  BT | 1.7±0.6 | 1.8±0.8 |  |
  AT | 1.8±0.9 | 1.6±0.7 |  |
  Difference (AT-BT) | 0.1±0.9 | -0.3±0.4 |  |
  Effect size | 0.17 | 0.38 |  |
  P valuea | 0.88 | 0.0017 |  |
Symptom severity score | Â | Â | 0.51 |
  BT | 2.5±0.8 | 2.6±0.8 |  |
  AT | 1.9±0.7 | 2.1±0.8 |  |
  Difference (AT-BT) | -0.5±0.7 | -0.5±0.7 |  |
  Effect size | 0.63 | 0.63 |  |
  P valuea | <0.0001 | 0.0046 |  |
Pain scale | Â | Â | 0.81 |
  BT | 56.3±20.9 | 68.3±19.3 |  |
  AT | 50.7±22.7 | 54.2±22.6 |  |
  Difference (AT-BT) | -5.7±24.1 | -14.2±27.3 |  |
  Effect size | 0.27 | 0.74 |  |
  P valuea | 0.29 | 0.01 |  |